Janossy G, Roberts M, Greaves M F
Lancet. 1976 Nov 13;2(7994):1058-61. doi: 10.1016/s0140-6736(76)90970-3.
On the basis of membrane marker analysis with an antiserum made against acute lymphoblastic leukaemia and other immunological markers it is suggested that some chronic myeloid leukaemias (C.M.L.) and some acute lymphoblastic leukaemias (A.L.L.) originate in a common target cell or precursor. This is possibly a pluripotential stem cell or a closely related derivative. These leukaemic cells retain their undifferentiated membrane characteristics C.M.L. patients in blast crisis who are A.L.L.-antigen-positive and have terminal transferase enzyme activity might benefit from therapy usually given in typical Philadelphia-chromosome-negative A.L.L.
基于用针对急性淋巴细胞白血病制备的抗血清进行的膜标记分析以及其他免疫标记,有人提出某些慢性粒细胞白血病(C.M.L.)和某些急性淋巴细胞白血病(A.L.L.)起源于共同的靶细胞或前体细胞。这可能是一个多能干细胞或与之密切相关的衍生物。这些白血病细胞保留其未分化的膜特征。处于原始细胞危象的C.M.L.患者,若其A.L.L.抗原呈阳性且具有末端转移酶活性,可能会从通常用于典型费城染色体阴性A.L.L.的治疗中获益。